Diamond Blackfan Anemia Treatment Market Size (7MM) is Projected to Grow at a CAGR of 3% by 2036, estimates DelveInsight

DelveInsight's "Diamond Blackfan Anemia Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Diamond Blackfan Anemia, historical and forecasted epidemiology as well as Diamond Blackfan Anemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Diamond Blackfan Anemia Treatment Market Report @ https://www.delveinsight.com/sample-request/diamond-blackfan-anemia-dba-aase-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Diamond Blackfan Anemia Market Report
• Among the 7MM, the United States accounted for the highest number of Diamond Blackfan Anemia Diagnosed Prevalent Cases in 2025, with nearly 6,000 cases. These cases are anticipated to increase by 2036.
• In the United States, the RPS19 mutation accounted for ~25% cases in 2025 among diamond blackfan anemia cases by mutation.
• Among the EU4 and the UK, approximately 25% of diamond blackfan anemia cases in 2025 were reported to be of the craniofacial type, followed by cases with musculoskeletal, urogenital, and other congenital anomalies.
• In Japan, among the congenital anomalies associated with Diamond-Blackfan anemia, craniofacial anomalies were the most prevalent, with almost 50 cases reported in 2025, followed by musculoskeletal anomalies.
• The leading Diamond Blackfan Anemia Companies include Disc Medicines, Apriligen, and others.
• Promising Diamond Blackfan Anemia Therapies include Bitopertin, APR-2020, and others.

Get a Free sample for the Diamond Blackfan Anemia Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/diamond-blackfan-anemia-dba-aase-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diamond Blackfan Anemia Overview
DBA is a rare inherited bone marrow disorder that typically presents in infancy and is characterized by a failure of red blood cell production due to mutations in ribosomal protein genes. It leads to severe macrocytic anemia with symptoms such as pallor, fatigue, poor feeding, and growth delay. Around 40%-50% of patients also have congenital abnormalities, including craniofacial defects, thumb malformations, short stature, and cardiac anomalies. The disease varies in severity and may also be associated with developmental issues and an increased risk of malignancies later in life.

Diamond Blackfan Anemia Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Diamond-Blackfan Anemia
• Total Diagnosed Prevalent Cases of Diamond-Blackfan Anemia (DBA) by Mutated Gene
• Total Diagnosed Prevalent Cases of Diamond-Blackfan Anemia (DBA) by Congenital Anomaly
• Total Treated Cases of Diamond Blackfan Anemia

Download the report to understand which factors are driving Diamond Blackfan Anemia epidemiology trends @ https://www.delveinsight.com/sample-request/diamond-blackfan-anemia-dba-aase-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diamond Blackfan Anemia Pipeline Analysis
• Bitopertin: Disc Medicines
Bitopertin is an oral, selective inhibitor of GlyT1, a key membrane transporter required to supply developing red blood cells with sufficient glycine to support heme synthesis. Heme biosynthesis is a multistep, enzymatic process that begins with glycine, which is a critical component of heme. By limiting glycine uptake, bitopertin can regulate downstream heme synthesis. These hematologic effects have been established in numerous preclinical and clinical studies of bitopertin. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.

• APR-2020: Apriligen
APR-2020, Apriligen's lead therapeutic candidate is an autologous solution for RPS19-deficient DBA patients. It has been granted Orphan Drug, Rare Pediatric Disease, Fast Track and Rare Disease Evidence Principles (RDEP) designations by the US Food and Drug Administration (FDA) and Orphan Drug Designation by the European Medicines Agency (EMA). The IND for APR-2020 was filed with the FDA in August 2025, and in September 2025, the FDA issued Apriligen a safe to proceed letter for APR-2020. Phase I FDA human clinical trials of APR-2020 began in 1Q2026. Trial sites have been selected in the United States. European trial sites are expected to open towards the end of 2H2026.

Diamond Blackfan Anemia Market Outlook
DBA is a rare blood disorder diagnosed in infancy, where the bone marrow fails to produce enough red blood cells. Current treatments, including glucocorticosteroids, blood transfusions, and HSCT, have limitations. Steroids can lose effectiveness over time and cause severe side effects, such as osteoporosis and diabetes. Blood transfusions risk iron overload, while HSCT, the only curative treatment, presents challenges like finding compatible donors and immunological complications. Corticosteroid (also called steroid) medicines: Steroids improve anemia and red blood cell counts in about 80% of patients with DBA. Steroids are strong medicines with potentially serious side effects. Steroid therapy may be lifelong for many patients with DBA.

Diamond Blackfan Anemia Companies
Disc Medicines, Apriligen, and others.

Discover more about therapies set to grab Major Diamond Blackfan Anemia market share @ https://www.delveinsight.com/sample-request/diamond-blackfan-anemia-dba-aase-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diamond Blackfan Anemia Market Outlook
DBA is a rare blood disorder diagnosed in infancy, where the bone marrow fails to produce enough red blood cells. Current treatments, including glucocorticosteroids, blood transfusions, and HSCT, have limitations. Steroids can lose effectiveness over time and cause severe side effects, such as osteoporosis and diabetes. Blood transfusions risk iron overload, while HSCT, the only curative treatment, presents challenges like finding compatible donors and immunological complications.

Diamond Blackfan Anemia Treatment Landscape
• Corticosteroid (also called steroid) medicines: Steroids improve anemia and red blood cell counts in about 80% of patients with DBA. Steroids are strong medicines with potentially serious side effects. Steroid therapy may be lifelong for many patients with DBA.
• Blood transfusions: Blood transfusions are often needed for anemia at diagnosis and usually for the first year of life. Transfusions may be given every three to four weeks as needed to increase the red blood cell count and provide adequate hemoglobin for growth and development. For patients who do not ultimately respond to treatment with steroids, blood transfusions are lifelong, along with management of iron overload. These patients may be candidates for a stem cell transplant or potentially gene therapy.
• Stem cell transplant: Stem cells are cells in the bone marrow that can become all types of blood cells. If an appropriately matched donor is found, then the donor's stem cells are given to the person with DBA. This may be a close family member, but the donor must be confirmed not to have DBA first. Sometimes an unrelated stem cell donor is used. A successful stem cell transplant will alleviate the anemia of DBA. However, rejection or infection is possible. So, a stem cell transplant is usually only done if steroids are not effective and the patient is receiving red cell transfusions every 3-4 weeks.

To know more about Diamond Blackfan Anemia Companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/diamond-blackfan-anemia-dba-aase-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diamond Blackfan Anemia Market Report
• Coverage- 7MM
• Study Period: 2022-2036
• Forecast Period- 2026-2036
• Diamond Blackfan Anemia Companies- Disc Medicines, Apriligen, and others.
• Diamond Blackfan Anemia Therapies- Bitopertin, APR-2020, and others.
• Diamond Blackfan Anemia Therapeutic Assessment- Diamond Blackfan Anemia current marketed and Diamond Blackfan Anemia emerging therapies
• Diamond Blackfan Anemia Market Dynamics: Diamond Blackfan Anemia market drivers and Diamond Blackfan Anemia market barriers
• Diamond Blackfan Anemia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Diamond Blackfan Anemia Unmet Needs, KOL's views, Analyst's views, Diamond Blackfan Anemia Market Access and Reimbursement

Table of Contents
1. Diamond Blackfan Anemia Market Report Introduction
2. Executive Summary for Diamond Blackfan Anemia
3. SWOT analysis of Diamond Blackfan Anemia
4. Diamond Blackfan Anemia Patient Share (%) Overview at a Glance
5. Diamond Blackfan Anemia Market Overview at a Glance
6. Diamond Blackfan Anemia Disease Background and Overview
7. Diamond Blackfan Anemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Diamond Blackfan Anemia
9. Diamond Blackfan Anemia Current Treatment and Medical Practices
10. Diamond Blackfan Anemia Unmet Needs
11. Diamond Blackfan Anemia Emerging Therapies
12. Diamond Blackfan Anemia Market Outlook
13. Country-Wise Diamond Blackfan Anemia Market Analysis
14. Diamond Blackfan Anemia Market Access and Reimbursement of Therapies
15. Diamond Blackfan Anemia Market Drivers
16. Diamond Blackfan Anemia Market Barriers
17. Diamond Blackfan Anemia Appendix
18. Diamond Blackfan Anemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.